<DOC>
	<DOCNO>NCT03001011</DOCNO>
	<brief_summary>Primary Objective : To demonstrate efficacy Renvela tablet reduction serum phosphorus hyperphosphatemia patient chronic kidney disease dialysis . Secondary Objectives : To document efficacy Renvela tablet reduction serum lipid ( total cholesterol low-density lipoprotein cholesterol [ LDL-C ] ) To document efficacy Renvela tablet reduction calcium-phosphorus product . To document efficacy Renvela tablet reduction intact parathyroid hormone ( iPTH ) . To document efficacy Renvela tablet proportion patient reach target serum phosphorus level ( 4.6 mg/dL [ 1.47 mmol/L ] , inclusive ) . To evaluate safety Renvela tablet .</brief_summary>
	<brief_title>Evaluation Renvela Patients With Chronic Kidney Disease Not On Dialysis And Hyperphosphatemia In China</brief_title>
	<detailed_description>The total duration study period per patient 14 week .</detailed_description>
	<mesh_term>Kidney Diseases</mesh_term>
	<mesh_term>Renal Insufficiency , Chronic</mesh_term>
	<mesh_term>Hyperphosphatemia</mesh_term>
	<mesh_term>Sevelamer</mesh_term>
	<criteria>Inclusion criterion : Patients chronic kidney disease dialysis , expect begin dialysis , renal transplantation next 4 month screen visit . Have serum phosphorus measurement ≥5.5 mg/dL ( 1.78 mmol/L ) Screening Visit ( patient phosphate binder [ ] Screening Visit ) OR end Washout Period ( patient phosphate binder [ ] Screening Visit ) . Have follow laboratory measurement Screening Visit : 25hydroxy vitamin D ≥10 ng/mL . iPTH ≤800 pg/mL . Willing able sign write informed consent . Exclusion criterion : Men woman 18 year age . Is level understand willingness cooperate visit procedure , describe study protocol . Not yet receive chronic kidney disease diet education screen visit . Not willing able avoid change diet study . Not willing able maintain screening dose lipid lower medication , 1 , 25 dihydroxy vitamin D , and/or cinacalcet duration study , except safety reason . Not willing able avoid antacid phosphate binder contain aluminium , magnesium , calcium , lanthanum duration study unless prescribe even calcium supplement . Have participate investigational drug study within 30 day , 5 half life , whichever longer , prior screen visit . Have know hypersensitivity sevelamer constituent Renvela tablet . Have bowel obstruction , active dysphagia swallow disorder , predisposition current bowel obstruction , ileus , severe gastrointestinal motility disorder include severe constipation . Using plan use antiarrhythmic antiseizure medication arrhythmia seizure disorder . Is pregnant breastfeeding . If patient female , childbearing potential ( premenopausal surgically sterile ) , willing use effective contraceptive method throughout study . Have condition , opinion investigator would prohibit patient 's inclusion study . The information intend contain consideration relevant patient 's potential participation clinical trial .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>December 2016</verification_date>
</DOC>